3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Colorectal Neoplasms
3
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia
2
Hodgkin Disease
2
Waldenstrom Macroglobulinemia
1
Tissue Adhesions
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pancreatic Neoplasms
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Myoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Mycosis Fungoides
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
plerixafor
1
Sodium Chloride
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Moxibustion
1
CP protocol
1
Anidulafungin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neutropenia
×
Sodium Chloride
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts